CA2821378A1 - Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms - Google Patents

Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms Download PDF

Info

Publication number
CA2821378A1
CA2821378A1 CA2821378A CA2821378A CA2821378A1 CA 2821378 A1 CA2821378 A1 CA 2821378A1 CA 2821378 A CA2821378 A CA 2821378A CA 2821378 A CA2821378 A CA 2821378A CA 2821378 A1 CA2821378 A1 CA 2821378A1
Authority
CA
Canada
Prior art keywords
akt
alkyl
inhibitor
autophagy
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2821378A
Other languages
English (en)
French (fr)
Inventor
Kui Lin
Michael Degtyarev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA2821378A1 publication Critical patent/CA2821378A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2821378A 2010-12-23 2010-12-23 Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms Abandoned CA2821378A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/062096 WO2012087336A1 (en) 2010-12-23 2010-12-23 Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms

Publications (1)

Publication Number Publication Date
CA2821378A1 true CA2821378A1 (en) 2012-06-28

Family

ID=46314300

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2821378A Abandoned CA2821378A1 (en) 2010-12-23 2010-12-23 Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms

Country Status (9)

Country Link
EP (1) EP2655619A4 (ja)
JP (1) JP2014507129A (ja)
KR (1) KR20130132956A (ja)
CN (1) CN103403161A (ja)
BR (1) BR112013015891A2 (ja)
CA (1) CA2821378A1 (ja)
MX (1) MX2013007171A (ja)
RU (1) RU2013134359A (ja)
WO (1) WO2012087336A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6052540B2 (ja) * 2012-12-21 2016-12-27 国立大学法人福井大学 Ａｔｇ７変異体を用いたオートファジーの抑制方法
EA201690004A1 (ru) 2012-12-27 2016-07-29 Санофи Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
KR101461916B1 (ko) 2013-11-04 2014-11-19 현대자동차 주식회사 커플드 토션 빔 액슬 타입 현가장치
WO2018143403A1 (ja) * 2017-02-03 2018-08-09 国立大学法人東北大学 複素環化合物
WO2018226776A1 (en) * 2017-06-08 2018-12-13 The Penn State Research Foundation Assay for monitoring autophagosome completion
JPWO2019112014A1 (ja) * 2017-12-07 2021-01-28 パール工業株式会社 選定分子の導入方法および阻害剤を含有する組成物
CN108103194B (zh) * 2017-12-27 2021-05-18 中国医学科学院药用植物研究所 一种抑制胃癌细胞mgc-803的靶点及其应用
KR102095749B1 (ko) * 2018-12-20 2020-04-01 충남대학교 산학협력단 S6k1 유전자 발현 억제제 또는 s6k1 단백질 활성 억제제를 유효성분으로 포함하는, 미토콘드리아 내 자가포식 장애로 발생되는 질병의 예방 또는 치료용 조성물
CN111593068B (zh) * 2019-01-28 2023-10-17 广州溯原生物科技股份有限公司 新型基因治疗载体pIRES-Rsirt2/4-Tet-nap的制备方法及应用
CN110592044B (zh) * 2019-07-26 2021-06-22 中国农业科学院蔬菜花卉研究所 蛋白激酶Fused编码基因及其在防治小菜蛾中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078774A2 (en) * 2005-01-19 2006-07-27 The Trustees Of The University Of Pennsylvania Regulation of autophagy and cell survival
CA2616537A1 (en) * 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US20100021420A1 (en) * 2006-07-14 2010-01-28 Astex Therapeutics Limited Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP2012528588A (ja) * 2009-06-05 2012-11-15 ソル，ダイ‐ウ 単一またはマルチ標的遺伝子を抑制するマルチ−シストロンｓｈＲＮＡ発現カセット

Also Published As

Publication number Publication date
JP2014507129A (ja) 2014-03-27
BR112013015891A2 (pt) 2016-10-04
EP2655619A4 (en) 2014-10-22
CN103403161A (zh) 2013-11-20
WO2012087336A1 (en) 2012-06-28
KR20130132956A (ko) 2013-12-05
EP2655619A1 (en) 2013-10-30
MX2013007171A (es) 2013-11-04
RU2013134359A (ru) 2015-01-27

Similar Documents

Publication Publication Date Title
CA2821378A1 (en) Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms
RU2680714C2 (ru) Комбинированная терапия для лечения рака
Liu et al. Mifepristone suppresses basal triple-negative breast cancer stem cells by down-regulating KLF5 expression
Frémin et al. ERK2 but not ERK1 plays a key role in hepatocyte replication: an RNAi‐mediated ERK2 knockdown approach in wild‐type and ERK1 null hepatocytes
Sriram et al. Triple combination of siRNAs targeting TGFβ1, TGFβR2, and CTGF enhances reduction of collagen I and smooth muscle actin in corneal fibroblasts
US20140004209A1 (en) Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms
CA2895690C (en) Apoptosis-inducing agent comprising suppressors of gst-.pi. and akt
KR20100038377A (ko) 암의 예방／치료제
US20190388426A1 (en) Perk and ire-1a inhibitors against neurodevelopmental disorders
Li et al. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells
CN107106657A (zh) 用于预防过早的卵泡活化的方法
Wang et al. Chemical screen identifies shikonin as a broad DNA damage response inhibitor that enhances chemotherapy through inhibiting ATM and ATR
US20220218734A1 (en) Combinations of therapeutic agents for treating uveal melanoma
US20200268753A1 (en) Perk and ire-1a inhibitors against neurodevelopmental disorders
Gopalan et al. Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma
Zhang et al. miR-196a-5p-rich extracellular vesicles from trophoblasts induce M1 polarization of macrophages in recurrent miscarriage
KR101541974B1 (ko) miR29b를 포함하는 신경줄기세포의 신경세포로의 분화 촉진용 조성물 및 방법
Wang et al. IGF-1 Promotes Epithelial-Mesenchymal Transition of Lens Epithelial Cells That Is Conferred by miR-3666 Loss
WO2014048071A1 (zh) 抑制PI3K/AKT/mTOR信号通路的药物组合和方法
US10238722B2 (en) Pigment epithelium derived factor (PEDF) for the treatment of uterine fibroids
KR102220965B1 (ko) 포스파티딜이노시톨 3-키나제 억제제 및 아로마타제 억제제를 포함하는 제약 조합물
JP2024504679A (ja) ｍｉＲ１４５阻害剤を有効成分として含む心筋梗塞の治療用組成物
Holm et al. Infantile hemangioma: the common and enigmatic vascular tumor
EP4288444A1 (en) Rationale, design, synthesis and validation of a small molecule anticancer agent
Langen GLYCOGEN SYNTHASE KINASE-3β IS REQUIRED FOR THE 2 INDUCTION OF SKELETAL MUSCLE ATROPHY 3

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20161223